

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Wei et al.
U.S. Serial No. : 10/650,365
Confirmation No. : 7677
Filed : August 28, 2003
Examiner : Jegatheesan Seharaseycon
Art Unit : 1647
For : RECOMBINANT SUPER-COMPOUND INTERFERON

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357

July 3, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

SUPPLEMENTAL RESPONSE TO AUGUST 23, 2005 OFFICE ACTION

This Amendment is being submitted as a Supplemental Response to the August 23, 2005 Office Action which was issued by the United States Patent and Trademark Office (USPTO) in connection with the above-identified application.

Priority

The Examiner acknowledged Applicants' claim for foreign priority based on an application filed in China on February 28, 2001. However, the Examiner also noted that Applicants did not file a

Applicant(s) : Wei et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 2

translated copy of the Application No. CHINA 01104367.9. Therefore the priority is set forth as the filing date of the instant application. Consequently, Applicants respectfully submit **Exhibit 1** (16 pages), which is the European counterpart of Applicant's International application referring to the same invention. It serves as the English translation of PCT/CN02/00128 and claims priority to Chinese Patent CN 01104367.9, filed on February 28, 2001.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant(s)
Law Offices of
Albert Wai-Kit Chan, PLLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 799-1000
Fax: (718) 357-8615
E-mail: chank@kitchanlaw.com

EXHIBIT 1

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)



EP 1 371 373 A1

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(43) Date of publication:

17.12.2003 Bulletin 2003/51

(51) Int Cl.7: A61K 38/21, A61P 1/16,

A61P 31/12, C12N 15/20,

C12N 15/63, C12N 15/70

(21) Application number: 02702211.0

(22) Date of filing: 28.02.2002

(86) International application number:

PCT/CN02/00128

(87) International publication number:

WO 02/080958 (17.10.2002 Gazette 2002/42)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: 28.02.2001 CN 01104367

(72) Inventors:

• WEI, Guangwen

Chengdu City, Sichuan 610017 (CN)

• GUO, Rongbing

Chengdu City, Sichuan 610017 (CN)

• ZHANG, Renhua

Chengdu City, Sichuan 610017 (CN)

(71) Applicant: Sichuan Biotechnology Research

Center

Chengdu City, Sichuan 610017 (CN)

(74) Representative: Capasso, Olga et al

de Simone & Partners

Via Vincenzo Bellini, 20

00198 Roma (IT)

(54) RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR

(57) The present invention relates to the use of recombination super compound interferon (rSIFN-co) as

hepatitis B surface antigen and e antigen inhibitor, in which the dimensional structure of said interferon protein has been changed.

Figure 1

```

5'   11      21      31      41      51
+1 N C D L P Q T H S L G N R R A L I L L A
1 ATGGTATT TACCTCACAC TCATTCCTT GGTAAACGTC CGCGCTCTGT TCTGCCTGGAA
TACACACTA ATGGTGGTT AGTTCAGAAGA CGATTCGGCG CGGAGAGACTA AGAACCGCGT

5'   71      81      91      1       11
+1 Q N R R X S P F S C L K D P R H D F G F P
61 CAGATGCGTCG CTATTCCTCC GTTTCAGTCG CGACAGACG CGCAGACGT CGGCTTTCGG
GCTTACGCG AGATAAAGGGG CAATTCGGCG GACTTTCTGG CAGTCTGAA CGCGGAAAGGC

5'   11      21      31      41      51      61      71
+1 Q B E F D G M O P Q K A Q A I A V L H E
121 CGAGTAGAAGT TGCTGGCAAC CGAAATTCAG AGATGTCGGG CGATTCCTGT ACTGGCACGA
GTTCTCTCA AGTACCGTT CGTTAACGTCG TTTCGAGTCG CGTACAGAGCA TGACGTCGCT

5'   91      1       11      21      31
+1 M I Q Q T F N L F S T K D B S A A N D E
181 ATGGTCCAC AGACCTCTCA CGCTGTTCTC ACCTAAGACA CGCTGCTGTCG TTGGGACGAA
TACTAGGTT TGTGGAGCTT GGACAGAGG TGATTTCTGG CGAGACGAA AACCCCTGCT

5'   51      61      61      71      81      91
+1 S L L E K F Y T E L Y R Q L N D L Z A C
241 AGCTGCTGG AGAGTGCTTA CACTGAACTG TATCAGCAGC TGAAAGCAGCT CGGAGCAGTC
TCGAACGACCG TGTGAACTGAC ATATGCGTCG ACTTCTGGG CGTTCTGGG CGTTCTGGG

5'   11      21      31      41      51
+1 V I Q E V G V S S T P L M N V D S I L R
301 GTRATCCAGG AGGTGGGT AGBAGAGACT CGCGCTGAGTA AGCTGGACTC TATTCGGCA
CATTAAGCTCC TGTACAGAAGA TCTTCTCTGA CGCGCTACT TGACGTCGAG ATAGACGCCGT

```

Description**FIELD OF THE INVENTION**

5 [0001] This invention is related to a recombinant super-compound Interferon (rSIFN-co) with changed dimensional structure. The characteristic of rSIFN-co in this invention is that it cannot only inhibit DNA (deoxyribonucleic acid) duplication of the hepatitis B virus but also the secretion of HBsAg and HBeAg.

BACKGROUND OF THE INVENTION

10 [0002] rSIFN-co is a new Interferon molecule constructed with the most popular conservative amino acid found in natural human α -IFN subtypes using genetic engineering methods. United States Patent Nos. 4,695,623 and 4,897,471 have described it. rSIFN-co had been proved to have broad-spectrum IFN activity and virus- and tumor-inhibition and natural killer cell activity. United States Patent No. 5,372,808 by Amgen, Inc. addresses treatment rSIFN-co. Chinese Patent No. 97193508.8 by Amgen, Inc. addresses re-treatment of rSIFN-co on hepatitis C. Chinese Patent No. 98114663.5 by Shenzhen Jilusheng Bio-engineering Ltd. addresses treatment of rSIFN-co on hepatitis B and hepatitis C.

15 [0003] The United States Food and Medicine Administration (FDA) authorized Amgen Ltd. to produce rSIFN-co with *E. Coli* for clinical hepatitis C treatment at the end of 1997.

20 [0004] Hepatitis B patients can be identified when detecting HBsAg and the HBeAg. α -IFN is commonly used in clinics to treat hepatitis B. IFN binds superficial cell membrane receptors, inhibiting DNA and RNA (ribonucleic acid) duplication, including inducing some enzymes to prevent duplication of the virus in hepatitis-infected cells. All IFNs can inhibit only the DNA duplication of viruses, not the e and s antigen.

DETAILED DESCRIPTION OF THE INVENTION**Invention Component**

25 [0005] It was surprising to find that rSIFN-co, the dimensional structure of which has been changed, is not only a preparation to inhibit the DNA duplication of hepatitis B, but to inhibit the secretion of HBsAg and HBeAg.

30 [0006] The objective of this invention is to offer a preparation of rSIFN-co to inhibit the DNA duplication of hepatitis B viruses and the secretion of HBeAg and HBsAg of hepatitis B and decrease them to normal levels.

35 [0007] *Results of this invention:* The production of rSIFN-co with recombinant techniques. On the condition of fixed amino acid sequence, the IFN DNA was redesigned according to the *E. Coli* codon usage and then the rSIFN-co gene was artificially synthesized.

[0008] rSIFN-co cDNA was cloned into the high-expression vector of *E. Coli* by DNA recombinant techniques, and a high expression of rSIFN-co was gained by using of induce/activate-mechanism of L-arabinose to activate the transcription of P_{BAD} promoter.

40 [0009] Compared with usual thermo-induction, pH induction and IPTG induction systems of genetic engineering, arabinose induction/activation system has some advantages: (1) Common systems relieve promoter function by creating a "derepression" pattern. Promoters then induce downstream gene expression. So temperature and pH change and the addition of IPTG cannot activate promoters directly. In the system disclosed herein, L-arabinose not only deactivates and represses but also activates the transcription of P_{BAD} promoter which induces a high expression of rSIFN-co. Therefore, the arabinose induction/activation system is a more effective expression system. (2) The relation between Exogenous and L-arabinose dosage is linearity. This means the concentration of arabinose can be changed to adjust the expression level of the exogenous gene. Therefore, it is easier to control the exogenous gene expression level in *E.coli* by arabinose than by changing temperature and pH value. This characteristic is significant for the formation of inclusion bodies. (3) L-arabinose is resourceful cheap and safe, which, on the contrary, are the disadvantages of other inducers such as IPTG.

45 [0010] This invention creates an effective and resistant rSIFN-co-expressing *E. Coli* engineering strain with an L-arabinose induction/activation system. The strain is cultivated and fermented under suitable conditions to harvest the bacterial bodies. Inclusion bodies are then purified after destroying bacteria and washing repeatedly. The end result, mass of high-purity, dimensional-structure-changed rSIFN-co protein for this invention and for clinical treatment, was gained from denaturation and rehydration of inclusion bodies and a series of purification steps.

50 [0011] The following are some rSIFN-co preparations: tablets, capsules, oral liquids, pastes, injections, sprays, suppositories, and solutions. Injections are recommended. It is common to subcutaneously inject or vein-inject the medicine. The medicine carrier could be any acceptance medicine carrier, including carbohydrate, cellulose, adhesive, collapse, emollient, filling, add-dissolve agent, amortization, preservative, add-thick agent, matching, etc.

DETAILED DESCRIPTION OF THE FIGURE

[0012] Figure 1. DNA coding sequence and deduced amino acid sequence of rSIFN-co

5 EXPERIMENTAL DETAILS

Embodiment experience:

[0013] The invention disclosed herein also experimentally verifies that the dimensional-structure-changed rSIFN-co
10 can inhibit HBV-DNA duplication and secretion of HBsAg and HBeAg.

Materials

[0014] Solvent and Dispensing Method: Add 1ml saline into each vial, dissolve, and mix with MEM culture medium
15 at different concentrations. Mix on the spot.

[0015] Control drugs: IFN- α 2b (Intron A) as lyophilized, purchased from Schering Plough. 8×10^6 U each, mix to
3 $\times 10^6$ U/ml with culture medium; INFERGEN (liquid solution), purchased from Amgen, 9 μ g, 0.3ml each, equal to
9 $\times 10^6$ U, and mix with 9 $\times 10^6$ U/ml culture medium preserve at 4°C; 2.2.15 cell: 2.2.15 cell line of hepatoma (Hep G2)
20 cloned and transfected by HBV DNA, constructed by Mount Sinai Medical Center.

[0016] Reagent: MEM powder, Gibco American Ltd; cattle fetal blood serum, HycloneLab American Ltd. G-418(Ge-
neticin); MEM dispensing, Gibco American Ltd.; L-Glutamyl, imported and packaged by JING KE Chemical Ltd.; HBsAg
25 and HBeAg solid-phase radiolimmunoassay box, Northward Reagent Institute of Chinese Isotope Ltd.; Biogracetina,
Northern China Medicine; And Lipofectin, Gibco American Ltd.

[0017] Experimental goods and equipment: culture bottle, Denmark Tunclon™; 24-well and 96-well culture board,
25 Corning American Ltd.; Carbon Dioxide hatching box, Shel-Lab American Ltd.; MEM culture medium 100ml; 10% cattle
fetal blood serum, 3% Glutamyl1%, G418 S80 μ g/ml, biogracetina50U/ml.

Method:

[0018] 2.2.15 cell culture: Added 0.25% pancreatic enzyme into culture box with full of 2.2.15 cell, digest at 37°C for
30 3 minutes, and add culture medium to stop digest and disturb it to disperse the cells, reproduce with ratio of 1:3. They
will reach full growth in 10 days.

[0019] Medicine toxicity test: In this test, set groups of different medicine concentrations and a control group in which
35 cell is not acted on with medicine. Digest cell, and dispense to a 100,000 cell/ml solution. Inoculate to 96-well culture
board, 200 μ l each well, culture at 37°C for 24h with 5% CO₂. Test when simple cell layer grows.

[0020] Dispense rSIFN-co to 1.8×10^7 U/ml solution than prepare a series of solutions diluted at two-fold gradients.
30 Add into 96-well culture board, 3 wells per concentration. Change the solution every 4 days. Test cytopathic effect by
microscope after 8 days. Fully destroy as 4, 75% as 3, 50% as 2, 25% as 1, zero as 0. Calculate average cell lesion
and inhibition rate of different concentrations. Calculate TC50 and TC0 according to the Reed Muench method.

$$TC50 = \text{Antilog} \left(B + \frac{50-B}{A-B} \times C \right)$$

A=log >50 % medicine concentration, B=log<50 % medicine concentration, C=log dilution power

[0021] Inhibition test for HBeAg and HBsAg: Separate into positive and negative HBeAg and HBsAg contrast groups,
45 cell contrast group and medicine concentration groups. Inoculate 700,000 cells/ml of 2.2.15 cell into 6-well culture
board, 3 ml each well, culture at 37°C for 24h with 5% CO₂, then prepare 5 gradually diluted solutions with 3-fold as
the grade (Prepare 5 solutions, each with a different protein concentration. The concentration of Solution 2 is 3 times
lower than that of Solution 1, the concentration of Solution 3 is 3 times lower than that of Solution 2, etc.) 4.5×10^6 U/
50 ml, 1.5×10^6 U/ml, 0.5×10^6 U/ml, 0.17×10^6 U/ml, and 0.056×10^6 U/ml, 1 well per concentration, culture at 37°C for
24h with 5% CO₂. Change solutions every 4 days using the same solution. Collect all culture medium on the 8th day.
Preserve at -20°C Repeat test 3 times to estimate HBsAg and HBeAg with solid-phase radiolimmunoassay box (North-
55 ward Reagent Institute of Chinese Isotope Ltd.). Estimate cpm value of each well with a γ -accounting machine.

[0022] Medicinal effects calculation: Calculate cpm mean value of contrast groups and different-concentration groups
and their standard deviation, P/N value such as inhibition rate, IC50 and SI.

$$1) \text{ Antigen inhibition rate (\%)} = \frac{A-B}{A} \times 100$$

[0023] A = cpm of control group; B = cpm of test group;
 2) Counting the half-efficiency concentration of the medicine

$$5 \quad \text{Antigen Inhibition IC50} = \text{Antilog} \left(B + \frac{50-B}{A-B} \times C \right)$$

A=log>50% medicine concentration, B=log<50 % medicine concentration, C=log dilution power
 3) SI of interspace-conformation changed rSIFN-co effect on HBsAg and HBeAg in 2.2.15 cell culture:

$$10 \quad SI = \frac{TC50}{IC50}$$

4) Estimate the differences in cpm of each dilution degree from the control group using student t test

15 [0024] Southern blot: (1) HBV-DNA extract in 2.2.15 cell: Culture cell 8 days. Exsuction culture medium (Separate cells from culture medium by means of draining the culture medium.) Add lysis buffer to break cells, then extract 2 times with a mixture of phenol, chloroform and Isoamyl alcohol (1:1:1), 10,000g centrifuge. Collect the supernatant adding anhydrous alcohol to deposit nucleic acid. Vacuum draw, redissolve into 20µlTE buffer. (2) Electrophoresis: Add 6XDNA loading buffer, electrophoresis on 1.5% agarose gel, 1V/cm, at fixed pressure for 14-1Bh. (3) Denaturation and hybridization: respectively dip gel into HCl, denaturation buffer and neutralization buffer. (4) Transmembrane: Make an orderly transfer of DNA to Hybond-N membrane. Bake, hybridize and expose with dot blot hybridization. Scan and analyze relative density with gel-pro software. Calculate inhibition rate and IC50.

Results

25 [0025] Results from Tables 1, 2 and 3 show: After maximum innocuous concentration exponent culturing for 8 days with 2.2.15 cell, the maxima is $9.0 \pm 0 \times 10^6$ IU/ml and the average inhibition rate of maximum innocuous concentration rSIFN-co to HBeAg is $46.0 \pm 5.25\%$ ($P < 0.001$), IC50 is $4.54 \pm 1.32 \times 10^6$ IU/ml, SI is 3.96; rate to HBsAg is $44.8 \pm 6.6\%$, IC50 is $6.49 \pm 0.42 \times 10^6$ IU/ml, SI is 2.77. This shows that rSIFN-co can significantly inhibit the activity of HBeAg and HBsAg, but that the IFN of the contrast group and INFERGEN cannot. It has also been proved in clinic that rSIFN-co can decrease HBeAg and HBsAg or return them to normal levels.

30 [0026] The following are some examples for the preparation of rSIFN-co:

Example 1: Preparation of lyophilized injection

[0027]

- a) rSIFN-co 3×10^6 IU
- b) citric acid 0.2 mg
- c) dibasic sodium phosphate 2.5 mg
- d) NaCl 4.0 mg
- e) dextran 20 mg
- f) Polyoxyethylene anhydrosorbitol monoelaeo-acids ester 0.1 ml
- g) Inject water to a level of 1.0 ml

45 [0028] Preparation technique: Weigh materials according to recipe. Dissolve with sterile and pyrogen-free water. Filter through 0.22µm membrane to de-bacterialize, preserve at 6-10°C. Fill in vials after affirming it is sterile and pyrogen-free. Add 1.0 ml solution to each bottle, and lyophilize in freeze dryer.

Example 2: Preparation of liquid injection

[0029]

- a) rSIFN-co 3×10^6 IU
- b) citric acid 0.2 mg
- c) dibasic sodium phosphate 2.5 mg
- d) NaCl 4.0 mg
- e) dextran 20 mg
- f) Polyoxyethylene anhydrosorbitol monoelaeo-acids ester 0.1 ml

EP 1 371 373 A1

g) inject water to a level of 1.0 ml

5 [0030] Preparation technique: Weigh materials according to recipe. Dissolve with sterile and pyrogen-free water. Filter through 0.22µm membrane to de-bacterialize, preserve at 6-10°C. Fill in airtight vial after affirming it is sterile and non-pyrogen at 1.0 ml per vial. Store end product at 2-10°C, and protect from light.

10

15

20

25

30

35

40

45

50

55

Table 1. Results of inhibition rate of rSIFN-co to HBeAg and HBSAg
First batch: (rSIFN-co)

Inhibition effect to HBeAg									
Concentration ($\times 10^4$ IU/ml)	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate		
	First well	Second well	Third well						
900	9026	8976	10476	0.436227	0.43935	0.345659	0.407079	0.945909	0.562921
300	9616	12082	10098	0.3953754	0.245347	0.369269	0.337997	0.5388299	1.754924
100	9822	16002	12800	0.386508	0.0005	0.2005	0.195836	0.200833	0.300392321
33.3333	15770	19306	18824	0.014991	0	0	0.004997	0.0045969	0.08867188
11.1111	19172	22270	18934	0	0	0	0	0	0.001633453
Control	Cell	16010	Blank	0	Dilution	3	IC50	4.054091	0
Inhibition effect to HBSAg									
Concentration ($\times 10^4$ IU/ml)	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate		
	First well	Second well	Third well						
900	7706	7240	7114	0.342155	0.381936	0.392693	0.372261	0.922258	0.627739
300	8856	7778	9476	0.2439816	0.336008	0.191053	0.257014	0.5499972	1.370726
100	10818	10720	10330	0.07649	0.084856	0.118149	0.093165	0.292983	2.27756
33.3333	10744	11114	10570	0.082807	0.051221	0.097661	0.07723	0.1998179	0.113977019
11.1111	10672	9352	10810	0.088953	0.201639	0.071173	0.122588	0.122588	0.058767408
Control	Cell	11714	Blank	0	Dilution	3	IC50	641.7736749	641.7736749

Second batch: (TBIFM-co)

Inhibition effect to HBsAg													
Concentration (x10 ⁴ RU/ml)	First well			Second well			Third well			Average inhibition rate	Accumulation	1- accumulation	Accumulated inhibition rate
	First well	Second well	Third well	First well	Second well	Third well	First well	Second well	Third well				
900	7818	8516	9350	0.554378	0.514592	0.4104567	0.394209	0.467054	0.467054	0.477884	0.477884	0.487892	0.73731972
300	10344	10628	9160	0.4104567	0.427497	0.427497	0.427497	0.427497	0.427497	0.427497	0.427497	0.427497	0.44756245
100	12296	14228	13262	0.299134	0.18903	0.244072	0.244072	0.244072	0.244072	0.244072	0.244072	0.244072	0.19201839
33.33333	15364	17414	16188	0.124259	0.00741	0.77291	0.669653	0.669653	0.669653	0.669653	0.669653	0.669653	0.06393386
11.11111	17386	13632	15406	0.009006	0.222982	0.121863	0.117951	0.117951	0.117951	0.117951	0.117951	0.117951	0.0348073
Control	Cell	16962	Blank	0	Dilution	3	Dilution	3	Dilution	3	IC50	IC50	365.9357846

Inhibition effect to HBsAg													
Concentration (x10 ⁴ RU/ml)	First well			Second well			Third well			Average inhibition rate	Accumulation	1- accumulation	Accumulated inhibition rate
	First well	Second well	Third well	First well	Second well	Third well	First well	Second well	Third well				
900	5784	6198	5792	0.493265	0.462353	0.497571	0.486063	0.486063	0.486063	0.486063	0.486063	0.493477	0.513937
300	7150	8534	8318	0.379771	0.259715	0.278452	0.30598	0.30598	0.30598	0.30598	0.30598	0.4070138	1.207957
100	9830	11212	10210	0.147294	0.027412	0.11433	0.096345	0.096345	0.096345	0.096345	0.096345	0.102434	2.111612
33.33333	13942	12368	13478	0	0	0	0	0	0	0	0	0.0050891	3.111612
11.11111	12418	11634	11352	0	0	0	0.015267	0.005089	0.005089	0.005089	0.005089	0.106523	0.001237728
Control	Cell	Blank	0	Dilution	3	Dilution	3	Dilution	3	IC50	IC50	IC50	611.0919568

55 50 45 40 35 30 25 20 15 10 5

Third batch: (xSTEN-cc)

Inhibition effect to HBsAg						
Concentration ($\times 10^4$ TU/ml)	First well	Second well	Third well	Inhibition rate		
				First well	Second well	Third well
900	9702	9614	8110	0.428016	0.433204	0.52187
300	8914	10032	8876	0.4744723	0.40856	0.47706
100	16112	12658	13914	0.0383221	0.251975	0.17851
33.3333	15080	12814	13288	0.110954	0.244547	0.21660
11.1111	21228	15366	15728	0	0.094093	0.07275
Control	Cell	17544	Blank	0	Dilution	3

Inhibition effect to HsAg						
Concentration ($\times 10^4$ TU/ml)	First well	Second well	Third well	Inhibition rate		
				First well	Second well	Third well
900	9616	6228	5346	0.496864	0.442035	0.52105
300	8542	8590	7096	0.734725	0.230425	0.36427
100	11420	11360	11394	0	0	0
33.3333	12656	11582	11110	0	0	0
11.1111	13142	12336	13342	0	0	0
Control	Cell	11528	Blank	0	Dilution	3

HBsAg: Average IC50: 450.2434 SD: 132.315479

HsAg: Average IC50: 649.1894 SD: 42.29580

5

10

15

20

25

30

35

40

45

50

55

Table 2: Results of inhibition rate of Interferon A(IFN- α 2b) to HBsAg and HBeAg

Inhibition effect to HBeAg						
Concentration ($\times 10^4$ TU/ml)	First well	Second well	Third well	Inhibition rate		
				First well	Second well	Third well
300	14918	11724	9950	0	0.029711	0.176529
100	14868	16890	15182	0	0	0
33.33333	16760	21716	16400	0	0	0
11.11111	20854	15042	16168	0	0	0
3.703704	12083	12083	12083	0	0	0
Control	Cell	17544	Blank	0	Dilution	3
					IC50	FALSE
Inhibition effect to HBsAg						
Concentration ($\times 10^4$ TU/ml)	First well	Second well	Third well	Inhibition rate		
				First well	Second well	Third well
300	9226	8196	9658	0.152489	0.247106	0.521054
100	10946	10340	10828	0	0.050156	0.364272
33.33333	122250	13934	0	0	0	0
11.11111	12634	12342	12000	0	0	0
3.703704	10886	10886	10886	0	0	0
Control	Cell	10886	Blank	0	Dilution	3
					IC50	FALSE

Table 3: Results of inhibition rate of Infergen to HBsAg and HBeAg
First batch: (Infergen)

Concentration ($\times 10^4$ TU/ml)	Inhibition effect to HBeAg								
	Inhibition rate			Average inhibition			1- Accumulation		
	First well	Second well	Third well	First well	Second well	Third well	rate	rate	rate
900	14172	12156	17306	0.091655	0.220869	0	0.104175	0.306157	0.895825
300	13350	12888	16252	0.1417767	0.212409	0	0.118062	0.2019827	1.777764
100	14364	18834	14194	0.079349	0	0.090245	0.056531	0.063921	0.102024519
33.33333	15722	16034	16340	0	0	0	0	0.0273897	0.029916678
11.11111	17504	17652	14320	0	0	0.082169	0.02739	0.02739	0.007306592
Control Cell	15602	Blank	0		Dilution	3		IC50	FALSE
Inhibition effect to HBsAg									
Concentration ($\times 10^4$ TU/ml)	Inhibition rate								
	First well	Second well	Third well	First well	Second well	Third well	Average inhibition	Accumulation	1- Accumulation
							rate	rate	rate
900	12080	11692	12234	0	0.01275	0	0.00425	0.025163	0.99575
300	12840	11484	12350	0	0.010313	0	0.010104	0.0209125	1.985645
100	12894	14696	15086	0	0	0	0	0.010808	2.985646
33.33333	15032	12920	13020	0	0	0	0	0.0108081	3.985646
11.11111	11754	11984	11508	0.004137	0	0.028287	0.010808	0.010808	0.012704416
Control Cell	11843	Blank	0		Dilution	3		IC50	FALSE

Second batch: (Infergen)

Inhibition effect to RBSAG													
Concentration ($\times 10^4$ TU/ml)	First well			Second well			Third well			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
	First well	Second well	Third well	First well	Second well	Third well	First well	Second well	Third well				
900	6278	6376	6408	0.200051	0.187564	0.183486	0.190367	0.271635	0.809633	0.253290505			
300	7692	9092	6394	0.0158777	0	0.18527	0.068383	0.0812678	1.74125	0.046161005			
100	8960	7474	8190	0	0	0.047655	0	0.015885	0.015985	2.725355	0.005724856		
33.33333	8530	8144	9682	0	0	0	0	0	0	3.725365	0		
11.11111	7848	7848	7848	0	0	0	0	0	0	4.723365	0		
Control	Cell	7948	Blank	0	Dilution	3	IC50	FALSE					

Inhibition effect to RBSAG													
Concentration ($\times 10^4$ TU/ml)	First well			Second well			Third well			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
	First well	Second well	Third well	First well	Second well	Third well	First well	Second well	Third well				
900	12364	12268	12274	0.036171	0.043655	0.043187	0.041004	0.140162	0.958996	0.12751773			
300	11590	12708	13716	0.0965076	0.093955	0	0.035287	0.0991581	1.923709	0.0490186			
100	12448	13468	13982	0.029623	0	0	0.009874	0.063871	2.913834	0.02144964			
33.33333	12616	11346	12444	0.016526	0.115529	0.029935	0.053996	0.053996	3.859838	0.013796309			
11.11111	12828	12828	12828	0	0	0	0	0	0	4.859838	0		
Control	Cell	12828	Blank	0	Dilution	3	IC50	FALSE					

5
10
15
20
25
30
35
40
45
50
55

Third batch: (Infergen)

Inhibition effect to HBsAg									
Concentration ($\times 10^4$ TU/mL)	First well	Second well	Third well	Inhibition rate			Average inhibitio n rate	Accumulatio n	1- Accumulatio n
				First well	Second well	Third well			
900	7240	6642	6158	0.064599	0.1418	0.20439	0.136951	0.217399	0.863049
300	11072	8786	6902	0	0	0	0.108246	0.03609	1.826596
100	7015	9726	7532	0.09354	0	0	0.024248	0.039276	0.044358
33.33333	7622	8866	8676	0.015245	0	0	0.005082	0.0150818	3.782601
11.11111	7740	7740	7740	0	0	0	0	0	1
Control	Cell	7740	Blank	0	Dilution	3	TC50	TC50	FALSE

Inhibition effect to HBeAg									
Concentration ($\times 10^4$ TU/mL)	First well	Second well	Third well	Inhibition rate			Average inhibitio n rate	Accumulatio n	1- Accumulatio n
				First well	Second well	Third well			
900	11048	11056	11902	0.04775	0	0	0.015917	0.015917	0.984083
300	13454	12896	11798	0	0	0	0	0	0.984083
100	12846	13160	12546	0	0	0	0	0	1.984083
33.33333	12680	12458	12360	0	0	0	0	0	2.984083
11.11111	11602	11602	11602	0	0	0	0	0	3.984083
Control	Cell	11602	Blank	0	Dilution	3	TC50	TC50	FALSE

HBeAg: Average IC50: 0 SD: 0

HBsAg: Average IC50: 0 SD: 0

Claims

- 5 1. A recombinant super-compound interferon (rIFN-co) with changed 3-dimensional structure and improved efficacy which can inhibit the DNA duplication and secretion of HBsAg and HBeAg of HBV.
- 10 2. The interferon of claim 1, wherein the 3-dimensional change was the result of changes of its production techniques, and efficacy gains not seen in interferon described in U.S. Patent Nos. 4,695,623 and 4,897,471.
- 15 3. A super-compound interferon of claim 1 or claim 2, wherein it has its unique secondary and tertiary structure which elicit its special efficacies.
- 20 4. A super-compound interferon of claim 1 or claim 2, produced by a highly efficient express system which is constructed with a special promoter.
- 25 5. The super-compound Interferon of claim 4, wherein the promoter is P_{BAD}.
- 30 6. The super-compound interferon of claim 4, wherein its gene is artificially synthesized cDNA, adjusted according to codon preference of *E. Coli*.
- 35 7. A process for production of recombinant super-compound interferon recited in claim 1 or 2,
- 40 8. The process for production of claim 7, comprising extraction of super-compound interferon from fermentation broth, collection of inclusion body, denaturation and renaturation of the harvested protein.
- 45 9. The process of claim 7, wherein the process maintains the high efficacy even when the super-compound interferon is used with an agent and in a particular concentration.
- 50 10. The process of claim 7, comprising separation and purification of the super-compound Interferon.
- 55 11. The process of claim 7, comprising lyophilization of purified super-compound interferon.
- 60 12. The process of claim 7, comprising production of liquid injection of super-compound interferon.
- 65 13. Uses of super-compound interferon in preparing medicines for inhibition of HBV-DNA, HBsAg and HBeAg, wherein the virus diseases comprising hepatitis A, hepatitis B, hepatitis C, other types of hepatitis, infections of viruses such as: Epstein-Barr virus, HIV, herpes viruses (Epstein-Barr virus, Cytomegalovirus, herpes simplex viruses), papovaviruses, poxviruses, picornaviruses, adenoviruses, rhinoviruses, human T cell leukaemia viruses I, or human T cell leukaemia viruses II.
- 70 14. Uses of claim 1 and 2, wherein the super-compound interferon selected for interferon is α , β , γ such as, IFN-1a, IFN-2b or other mutants.
- 75 15. Uses of claim 13, wherein super-compound interferon was administered via oral, vein injection, muscle injection, subcutaneous injection, nasal, or mucosal administration.
- 80 16. Uses of claim 13, wherein super-compound Interferon was administered following the protocol as follows: injection 9 μ g or 15 μ g per day, 3 times a week, total 24 weeks.

50

55

Figure 1

5' 11 21 31 41 51
 +1 M C D L P Q T H S L G N R R A L I L L A
 1 ATGTGTGATT TACCTCAAAAC TCATTCTCTT GGTAACCGTC GCGCTCTGAT TCTGCTGGCA
 TACACACTAA ATGGAGTTG AGTAAGAGAA CCATTGGCAG CGCGAGACTA AGACGACCGT

5' 71 81 91 1 11
 +1 Q M R R I S P F S C L K D R H D F G F P
 61 CAGATGCGTC GTATTCCCCC GTTAGCTGC CTGAAAGACC GTCACGACTT CGGCTTCCG
 GTCTACGCAG CATAAAGGGG CAAATCGACG GACTTCTGG CAGTGCTGAA GCCGAAAGGC

5' 31 41 51 61 71
 +1 Q E E F D G N Q F Q K A Q A I S V L H E
 121 CAAGAACAGT TCGATGGCAA CCAATTCCAG AAAGCTCAGG CAATCTCTGT ACTGCACGAA
 GTCTTCTCA AGCTACCGTT GGTTAAGGTC TTTCGAGTCC GTTAGAGACA TGACGTGCTT

5' 91 1 11 21 31
 +1 M I Q Q T F N L F S T K D S S A A W D E
 181 ATGATCCAAC AGACCTTCAA CCTGTTTCC ACTAAAGACA GCTCTGCTGC TTGGGACGAA
 TACTAGGTTG TCTGGAAGTT GGACAAAAGG TGATTCTGT CGAGACGACG AACCCGTGCTT

5' 51 61 71 81 91
 +1 S L L E K F Y T E L Y Q Q L N D L E A C
 241 AGCTTGCTGG AGAAGTTCTA CACTGAACGT TATCAGCAGC TGAACGACCT GGAAGCATGC
 TCGAACGACCC TCTTCAAGAT GTGACTTGAC ATAGTCGTCG ACTTGCTGGA CCTTCGTACG

5' 11 21 31 41 51
 +1 V I Q E V G V E E T P L M N V D S I L A
 301 GTAATCCAGG AAGTTGGTGT AGAAGAGACT CGCGCTGATGA ACCTCGACTC TATTCTGGCA
 CATTAGGTCC TTCAACCACA TCTTCTCTGA GGCGACTACT TGCAGCTGAG ATAAGACCGT

INTERNATIONAL SEARCH REPORT		International application No. PCT/CN02/00128
A. CLASSIFICATION OF SUBJECT MATTER		
IPC ⁷ : A61K38/21, A61P1/16, A61P31/12, C12N15/20, C12N15/63, C12N15/70 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC ⁷ : A61K38/21, A61P1/16, A61P31/12, C12N15/20, C12N15/63, C12N15/70		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Chinese Patents, Chinese Scientific and Technical Journals		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPOQUE, BA, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category ^a	Citation of document, with indication, where appropriate, of the relevant passages A WO9321229(AMGEN INC et al), 28. Oct. 1993 see abstract	Relevant to claim No. 1-16
A	WO8304053(AMGEN INC et al), 24. Nov. 1983 see abstract	1-16
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 23. July. 2002(23. 07. 02)	Date of mailing of the international search report 08 AUG 2002 (08. 08. 02)	
Name and mailing address of the ISA/CN 6 Kitucheng Rd., Jinmen Bridge, Haidian District, 100088 Beijing, China Facsimile No. 86-10-62019451	Authorized officer SUN, guangxiu Telephone No. 86-10-62093884	

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN02/00128

Patent document cited in search report	Publication date	Patent family members	Publication date
WO 9321229	1993-10-28	US5372808 EP0641359 CN1081909 JP7505894T	1994-12-13 1995-03-08 1994-02-16 1995-06-29
WO 8304053	1983-11-24	EP0108128 JP59501097T US4897471	1984-05-16 1984-06-28 1990-01-30

Form PCT/ISA/210 (patent family annex) (July 1998)